uniQure N.V. Faces Class Action Lawsuits for Alleged Misleading Statements to Investors

uniQure N.V. Faces Class Action Lawsuits Over Allegations of Misleading Statements

uniQure N.V. is embroiled in significant legal challenges as multiple law firms announce class action lawsuits on behalf of investors who purchased the company’s ordinary shares during a designated Class Period from September 24, 2025, to October 31, 2025. The Rosen Law Firm was among the first to publicly announce its involvement, detailing that it has already filed a lawsuit alleging that uniQure misrepresented crucial aspects of its Pivotal Study design, particularly regarding the approval status from the U.S. Food and Drug Administration (FDA). The allegations highlight that uniQure did not obtain full FDA approval for its study's design and downplayed the potential for delays in its Biologics License Application (BLA), which could impact the company's operational projections and prospects.

The misrepresentations outlined in the lawsuits could have significant repercussions for uniQure, potentially resulting in damages for affected shareholders as they seek recovery for their losses. The complaints assert that the company’s misleading public statements created an unrealistic basis for investor confidence, ultimately leading to deteriorated market trust when the true state of the FDA approval process and study designs became known. As the situation unfolds, shareholders who felt they were misled are encouraged to consider joining these class action suits and to appoint lead plaintiffs by the April 13, 2026, deadline set by the respective law firms.

Law firms stress the importance of selecting experienced counsel, citing impressive histories of successful recoveries in similar cases. The Rosen Law Firm, for example, emphasizes that it has achieved settlements totaling hundreds of millions of dollars for investors. The firm has also built a strong reputation, being recognized by ISS Securities Class Action Services for its successful track record in securities class actions. As the legal landscape continues to evolve, it remains vital for shareholders of uniQure to stay informed about their rights and available options regarding these class action lawsuits.

Additional Context:

DJS Law Group and The Schall Law Firm have also joined in filing similar class actions, each urging affected investors to consider their participation. The allegations focus on violations of the Securities Exchange Act of 1934, asserting that uniQure engaged in false and materially misleading statements about its clinical trials and the associated regulatory processes. In the wake of these developments, uniQure’s shareholders are advised to act promptly to secure their positions in potential litigation as deadlines approach and details are solidified.

As this situation progresses, both the company and investors will be closely monitoring the outcomes of these lawsuits, which may have wider implications for uniQure’s reputation and future activities within the biotechnology landscape, particularly regarding its ongoing development and regulatory approval processes.